Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …

Metabolic reprogramming in cancer is not only a biological hallmark but also reveals
treatment vulnerabilities. Numerous metabolic molecules have shown promise as treatment …

Hematologic malignancies are one of the most common cancers, and the incidence has
been rising in recent decades. The clinical and molecular features of hematologic …

Somatic mutations in isocitrate dehydrogenase (IDH) genes occur frequently in adult acute
myeloid leukemia (AML) and less commonly in pediatric AML. The objective of this study …

Abstract The US Food and Drug Administration has approved a total of 37 new drugs in
2022, which are composed of 20 chemical entities and 17 biologics. In particular, 20 …

Although kinase inhibitors (KI) frequently portray large interpatient variability, a 'one size fits
all'regimen is still often used. In the meantime, relationships between exposure-response …

Biological events that contribute to the pathogenesis of myelodysplastic
syndromes/neoplasms (MDS) are becoming increasingly characterized and are being …

Simple Summary Treatment of acute myeloid leukemia continues to progress. Although a
number of therapies are efficacious in treating acute myeloid leukemia, some are intolerable …

The discovery of isocitrate dehydrogenase 1 (IDH1) mutations in acute myeloid leukemia
(AML) and the resounding success of molecularly targeted therapies in related myeloid …